Vanda Pharmaceuticals Inc.
Bysanti
major depressive disorder (MDD)
Countdown
267days
Phase 3 readout · ~ Mar 31, 2027 estimated
What's at stake
Phase 3 trial results for Bysanti in major depressive disorder (MDD) are due ~ Mar 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The Phase III study of BYSANTI TM as a once-daily adjunctive treatment for major depressive disorder (MDD), with results expected in Q1 2027.”